PD-1 versus PD-L1 immunotherapy combined with chemotherapy, with or without bevacizumab, for advanced cervical cancer.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 2/3 trial compares a PD-1 antibody versus a PD-L1 antibody each given with standard chemotherapy, with the option of adding bevacizumab, in adults with metastatic, persistent, or recurrent cervical cancer. Participants must have histologically confirmed disease, ECOG performance status 0–1, and available tissue for PD-L1 testing. Key exclusions include another active invasive malignancy and pregnancy or lactation. The trial is being run at the N.N. Alexandrov National Cancer Centre in Minsk and follows standard safety and efficacy monitoring for immunotherapy and chemotherapy combinations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18-≤75 years.
* Histologically confirmed diagnosis.
* One of the forms of the cervical cancer:

  1. Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
  2. Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
  3. Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).
* Availability of material for determining PD-L-1 expression for immunotherapy candidates.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* No contraindications to chemotherapy, immunotherapy, or bevacizumab.
* Signed informed consent to participate in the study.

Exclusion Criteria:

* Presence of another active malignant invasive neoplasm.
* Pregnancy or lactation period.

Where it's running

• N.N. Alexandrov National Caner Centre
  Minsk, Lesnoy, Belarus Recruiting

Study contacts

• Study coordinator: Yana Kamko
• Email: kazache.yana@gmail.com
• Phone: 80259111218

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHR-A2102 versus investigator's choice chemotherapy for recurrent or metastatic cervical cancer after platinum and PD-(L)1 therapy

  This trial tests whether SHR-A2102 works better than standard chemotherapy for people with recurrent or metastatic cervical cancer whose disease progressed after platinum-based chemotherapy and PD-(L)1 inhibitors.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07418749

• Understanding cervical cancer treatment and characteristics in Italy

  This study looks at how patients in Italy with advanced or recurring cervical cancer are treated and what their experiences are like.

  Recruiting at 10 sites MSD Italia S.r.l. · Bologna, Bologna and 10 other locations · NCT06771193

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• HAIC plus QL1706 and bevacizumab as first-line therapy for unresectable HER2-negative intrahepatic cholangiocarcinoma

  This study tests a liver-directed chemotherapy plus immune therapy and a blood vessel blocker to see if it helps people with unresectable intrahepatic cholangiocarcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07841574

• Bevacizumab for severe HHT-related nosebleeds

  This study tests whether bevacizumab can help people with hereditary hemorrhagic telangiectasia who have severe nosebleeds.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07828015

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.